20 completed, 4 active not recruiting, 2 not yet recruiting, 2 recruiting. 11 Phase 4, 10 Phase 2, 4 Phase 3, 2 Phase 1, 1 Early Phase 1.
Follow Qsymia: new trials by email Literature Review of Qsymia trials Research Report on Qsymia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Weight Gain Prevention in Adolescents and Young Adults Qsymia 7.5 miligrams (mg)-46 mg Extended Release Capsule, Placebo - Healthy Volunteers | Phase 3 | Not yet recruiting | University of Minnesota | 140 | 2026-11-01 | 2026-06-04 |
| Obesity Treatment With Phentermine-Topiramate ER in AYA Surviving Leukemia and Lymphoma Phentermine/Topiramate ER, Health Behavior and Lifestyle Counseling - Acute Lymphoblastic Leukemia in Remission, Hodgkin Lymphoma in Remission | Phase 2 | Not yet recruiting | St. Jude Children's Research Hospital | 100 | 2026-10-01 | 2026-09-23 |
| Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder Group Therapy Program, semaglutide, Phentermine-Topiramate - Bipolar I Disorder, Bipolar II Disorder | Phase 4 | Recruiting | Mayo Clinic | 100 | 2026-01-19 | 2026-03-11 |
| Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo - Hypothalamic Obesity, Hypothalamic Tumor | Phase 2 | Active not recruiting | Seattle Children's Hospital | 24 | 2025-03-01 | 2026-10-16 |
| Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) Comprehensive weight loss, Enhanced lifestyle changes, Tirzepatide - Obesity | Phase 4 | Active not recruiting | The Cleveland Clinic | 150 | 2025-03-01 | 2026-09-30 |
| Phentermine/Topiramate as Preventive Pharmacotherapy for Obesity Qsymia and lifestyle management therapy, Placebo and lifestyle management therapy - Obesity, Adolescent | Phase 2 | Withdrawn | University of Minnesota | 2023-10-17 | 2023-10-26 | |
| Anti-obesity Pharmacotherapy and Inflammation Semaglutide, Phentermine-Topiramate combination, Phentermine - Obesity | Active not recruiting | Louisiana State University Health Sciences Center in New Orleans | 30 | 2023-06-01 | 2025-09-09 | |
| A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America Semaglutide, Orlistat, Phentermine/Topiramate - Obesity | Phase 4 | Completed | Novo Nordisk A/S | 500 | 2023-01-19 | 2026-01-14 |
| Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity Phentermine/Topiramate (Qsymia), Placebo - Pediatric Obesity | Early Phase 1 | Active not recruiting | University of Minnesota | 13 | 2022-07-07 | 2026-05-22 |
| A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects VI-0521, Phentermine, Placebo - Blood Pressure | Phase 4 | Completed | VIVUS LLC | 565 | 2022-01-25 | 2024-07-17 |
| Phase IV Study of Qsymia in Obese Patients Qsymia 3.75Mg-23Mg Extended Release Capsule, Qsymia 7.5Mg-46Mg Extended Release Capsule, Qsymia 11.25Mg-69Mg Extended Release Capsule - Obesity | Phase 4 | Completed | Alvogen Korea | 232 | 2021-09-17 | 2024-01-31 |
| Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity Phentermine-Topiramate, Meal Replacement Therapy, Placebo - Obesity | Phase 2 | Completed | University of Minnesota | 100 | 2021-08-04 | 2026-05-26 |
| Phentermine/Topiramate for Uric Acid Stones Phentermine / Topiramate Oral Product, Citrate Salts, Allopurinol, Diet - Obesity, Uric Acid Stones | Phase 2 | Completed | University of Florida | 19 | 2021-03-31 | 2026-06-15 |
| Pharmacologic Weight Loss as Adjunct Therapy for Ulcerative Colitis in Obese Patients Phentermine-Topiramate, Placebo - Colitis, Ulcerative, Obesity | Phase 2 | Recruiting | University of California, San Diego | 40 | 2020-12-18 | 2023-05-16 |
| Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker Phentermine-Topiramate Extended Release, Placebo, Online support system - Obesity | Phase 4 | Completed | Mayo Clinic | 80 | 2020-06-03 | 2023-06-22 |
| A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity VI-0521 oral capsule, Placebo oral capsule, Lifestyle Modification - Adolescent Obesity, Obesity in Adolescence | Phase 4 | Completed | VIVUS LLC | 223 | 2019-05-02 | 2022-09-10 |
| Individualized Obesity Pharmacotherapy Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion - Obesity | Phase 3 | Completed | Mayo Clinic | 193 | 2017-12-11 | 2023-07-18 |
| EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS) Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA - Polycystic Ovary Syndrome, Obesity | Phase 3 | Completed | Woman's | 119 | 2016-03-22 | 2021-01-29 |
| A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents Placebo, VI-0521 Mid Dose, VI-0521 Top Dose - Pediatric Obesity, Childhood Obesity | Phase 4 | Completed | VIVUS LLC | 42 | 2016-03-01 | 2022-08-23 |
| FDA Approved Medication to Reduce Binge Eating and/or Purging Phentermine/Topiramate-First, Placebo - Binge Eating Disorder, Bulimia Nervosa | Phase 1 | Completed | Stanford University | 22 | 2015-10-30 | 2018-05-14 |
Showing 20 of 29. Sign in to see all of them.
Obesity (18) · Pediatric Obesity (4) · Weight Loss (3) · Binge-Eating Disorder (2) · Bipolar Disorder (1) · Bulimia (1) · Bulimia Nervosa (1) · Colitis, Ulcerative (1) · Craniopharyngioma (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Dyslipidemias (1) · Glucose Intolerance (1) · Glucose Metabolism Disorders (1) · Hypothalamic Neoplasms (1)
VIVUS LLC (7) · Mayo Clinic (4) · University of Minnesota (4) · Alvogen Korea (1) · Denver Health and Hospital Authority (1) · Lindner Center of HOPE (1) · Louisiana State University Health Sciences Center in New Orleans (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Novo Nordisk A/S (1) · Seattle Children's Hospital (1) · St. Jude Children's Research Hospital (1) · Stanford University (1) · The Cleveland Clinic (1) · University of California, San Diego (1) · University of Florida (1)
United States (26) · South Korea (1)
Aaron Kelly, PhD (2) · Andres Acosta, MD, PhD (1) · Andres J Acosta (1) · Anna Guerdjikova, PhD,LISW (1) · Barbara Troupin, MD, MBA (1) · Bartolome Burguera, M.D (1) · Benjamin Canales, MD (1) · ChangBeom Lee, M.D., Ph.D. (1) · Chris Galloway, MD (1) · Christian L Roth, MD (1) · Craig Peterson (1) · Daniel H Bessesen, MD (1) · Daniel Hsia, M.D. (1) · Debra L Safer, MD (1)
PMID 22158731, PMID 25249652, PMID 25486131, PMID 28455281, PMID 29038069, PMID 29980535, PMID 30013815, PMID 30257072, PMID 31485965, PMID 31721257, PMID 33759389, PMID 34097062, PMID 36968652, PMID 38304225, PMID 40518455, PMID 41562388
R01DK067071 (1), R21DK122317 (1), U24DK132740 (1), UL1TR000135 (1)